Abstract:Abstract Therapeutic antibodies have revolutionized the way we treat cancer. Enhanced activity of therapeutic IgG can be achieved by the modulation of Fc binding to Fcγ receptors (FcγR), which will consequently modulate the Fc-effector functions triggered upon crosslinking of target and effector cells by these antibodies. Assessment of therapeutic antibodies pharmacodynamic (PD) in preclinical models is challenging, as the FcγR are different from mice to human, as well as their expression pattern. FcRn is involved in the recycling and transport of IgG and is a key determinant of the pharmacokinetics (PK) of IgG. We report here a novel mouse model expressing human FcγR with a human-like expression pattern, in which human FcγRI, FcγRIIA, FcγRIIB, FcγRIIIA, FcγRIIIB are expressed and replace their mouse orthologs. The model was intercrossed with the hSA/hFcRn mouse model (Viuff et al., 2016), which has shown to improve translatability of PK assessment of therapeutics with extended half-life via FcRn recycling and/or HSA binding. Investigation of FcγRI, FcγRIIA, FcγRIIB, FcγRIIIA, FcγRIIIB expression on DC, monocytes, granulocytes, NK, T and B cells shows that expression pattern in hFcγR mice is consistent with their expression on human PBMC, with a few exceptions. These receptors are functional, as a human IgG1 targeting mouse CD20 induces approximately 50% of B-cell depletion in blood and liver, after a single iv administration in hFcγR mice. This depletion is Fc-mediated, as it is abrogated when hFcγR mice are treated with an anti-mouse CD20 human IgG1 with a Fc-null mutation. Assessment of antibody-dependent cell cytotoxicity (ADCC) ex vivo to investigate FcγR functionality in NK cells shows that Rituximab, an anti-human CD20 chimeric IgG1 with regular Fc, induces higher ADCC efficacy in NK cells from hFcγR than in NK cells from WT mice. Obinutuzumab, an anti-human CD20 featuring an optimized Fc portion to enhance binding to FcγRIII, shows higher tumor cell lysis than Rituximab in NK cells from hFcγR mice, suggesting this model enables ranking of antibodies. Moreover, assessment of activity of Fc-engineered anti-influenza IgG antibodies also shows that anti-Flu antibody with enhanced Fc binding outperforms the WT antibody, improves protective activity, and demonstrates effector function in influenza challenge model, following prophylactic treatment. Conversely, hFcγR mice treated with an Fc-null version of the anti-Flu antibody shows reduced protective activity and survival compared with the WT antibody. Therefore, the model reported here is a novel tool for testing efficacy of Fc-engineered therapeutic antibodies. We are currently investigating the PK profile of therapeutic antibodies in the hFcγR/hSA/hFcRn model. This novel tool is being improved to enable tolerability to human IgG1, biodistribution to the central nervous system, and flexibility of test of therapeutics through expression of human immune checkpoints. Citation Format: Fabiane Sonego, Angela Pappalardo, Gaëlle Martin, Rachel Courtois, Séverine Augier, Yacine Cherifi, Ariane Morel, Patricia Isnard-Petit, Kader Thiam. Novel FcγR humanized mouse model enables assessment of PK/PD of therapeutic antibodies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5341.

Abstract 2954: Humanized CCR8 Mouse Model Provides a Translational Tool for Anti-Human CCR8 Antibody Drug Development

Abstract 2584: Development of an Fc gamma receptor fully-humanized mouse model to support the accurate preclinical study of therapeutic antibodies

Abstract LB130: Identification of fully human CCR8 antibodies that demonstrate excellent ADCC function, potent blocking activity, and robust anti-tumor immune responses

Abstract 2340: Development of a CCR8 Monoclonal Antibody Which Blocks CCR8 Signaling and Abolishes the Immunosuppressive Function of Treg for the Treatment of Cancer

Abstract 3256: TIGIT Humanized BALB/c Mouse: A Novel Animal Model for Preclinical Studies of Human TIGIT Antibodies

Abstract 5669: Establishment of a Human CD3ε Transgenic Mouse Model to Assess Anti-Tumor Efficacy of Human T-cell-redirecting Bispecific Antibodies

Abstract 718: CCR8 antibody drug conjugates: Targeting regulatory T cells for tumor sensitization

711 HBM1022, a Novel Anti-Ccr8 Antibody Depletes Tumor-Infiltrating Regulatory T Cells Via Enhanced ADCC Activity, Mediates Potent Anti-Tumor Activity with Keytruda

Abstract 5623: CD137 humanized mice for preclinical efficacy evaluation of therapeutic antibodies

Abstract 5346: A novel humanized CD16A model to evaluate efficacy of human antibody therapeutics in triggering ADCC

Abstract 1661: Humanized Mouse Models for Immune-Oncology Biotherapeutics: Development, Validation and Applications

Abstract 5292: CD28 humanized mouse model for efficacy and safety assessment of CD28-targeting therapies

Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody

Abstract 1645: Advancing the Development of CD16A-based Bispecific Antibodies in Humanized CD16A Mouse Models

Abstract 5674: Anti-CCR8-based bispecific antibodies engineered to preferentially eliminate tumor-infiltrating regulatory T cells: leaving effectors unharmed

Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs

Abstract 123: Establishment of humanized CD3EDG/4-1BB mice for testing novel T cell engagers

Abstract 5341: Novel FcγR humanized mouse model enables assessment of PK/PD of therapeutic antibodies

Development of a CCR8 monoclonal antibody to block CCR8 signaling and to abolish the immunosuppressive function of Treg for the treatment of cancers.

Abstract 6350: 2MW4691, a novel CCR8/CTLA-4 bispecific antibody, displays potent anti-tumor efficacy by specifically depeleting tumor-infiltrating Tregs and blocking CTLA-4 signaling on CD8+ T cells

Abstract 5615: Anti-human CD47 antibody Hu5F9 inhibits MC38 tumor growth in hCD47/hSIRPα double knock-in mice